The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2023 and forecasted to 2032

North America held the largest psoriatic arthritis treatment market share.

The global psoriatic arthritis treatment market is expected to grow from $8.92 billion in 2022 to $9.94 billion in 2023 at a compound annual growth rate (CAGR) of 11.4%. The psoriatic arthritis treatment market is expected to grow from $14.36 billion in 2027 at a CAGR of 9.6%.

Major Driver In The Psoriatic Arthritis Treatment Market ­– Rise In The Prevalence Of Psoriasis And Psoriatic Arthritis
According to the National Psoriasis Foundation, a US-based healthcare organisation, more than 8 million people in the United States and 125 million people globally suffered from psoriasis, a chronic immune-mediated disorder, in June 2021. Furthermore, around 30% of patients with psoriasis develop psoriatic arthritis in the United States. As a result, rising prevalence of psoriasis and psoriatic arthritis fuels market expansion.

View More On The Psoriatic Arthritis Treatment Market Report 2023 – https://www.thebusinessresearchcompany.com/report/psoriatic-arthritis-treatments-global-market-report

Key Psoriatic Arthritis Treatment Market Segments
1) By Drug Class: Nonsteroidal Anti-Inflammatory Drugs (NSAIDS), Disease-Modifying Anti-Rheumatic Drugs (DMARDS), Biologics, Other Drug Classes
2) By Route Of Administration: Oral, Parenteral, Topical
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Recent Psoriatic Arthritis Treatment Market Trend – Developing Novel Drugs
The market is being shaped by the development of innovative medications such as Janus kinase (JAK) inhibitors for the treatment of psoriatic arthritis. Janus kinase (JAK) inhibitors are tiny compounds that are taken orally and are emerging as a potential treatment for psoriatic arthritis sufferers. Tofacitinib, baricitinib, and upadacitinib are the three JAK inhibitors approved for the treatment of autoimmune disorders. The first Janus kinase (JAK) inhibitors approved by the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) are Xeljanz (tofacitinib) and Xeljanz (tofacitinib) XR. They are used to treat adult patients with active psoriatic arthritis (PsA) who have had insufficient or intolerable responses to methotrexate or other disease-modifying antirheumatic medications (DMARDs). In June 2020, AbbVie, a large US-based pharmaceutical firm, said that it had applied to the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for approval of upadacitinib (RINVOQ), a JAK inhibitor.

Psoriatic Arthritis Treatment Market Prominent Players
Major players in the psoriatic arthritis treatment market are AbbVie, Amgen, Johnson & Johnson, Bristol-Myers Squibb Company, Celgene Corporation, Novartis, Eli Lilly and Company, Pfizer, UCB Biosciences Inc., and Hoffmann La Roche Ltd.

Request A Sample Of The Global Psoriatic Arthritis Treatment Market Report 2023:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3458&type=smp

The Psoriatic Arthritis Treatment Global Market Report 2023  provides a comprehensive overview on the psoriatic arthritis treatment market size, trends and drivers, opportunities, strategies, and companies analysis. The countries covered in the psoriatic arthritis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA, and the major seven regions are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

A form of treatment or substance used to stop or diminish a chronic inflammatory illness of the joints and the places where tendons and ligaments attach to the bones (entheses) is referred to as psoriatic arthritis treatment. This treatment focuses on skin involvement as well as joint discomfort and impairment.

View More Related Reports –
Arthritis Monoclonal Antibodies Global Market Report 2023
Ovarian Cancer Drugs Global Market Report 2023
Tumor Necrosis Factor Inhibitor Drugs Global Market Report 2023

Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]

Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model